

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6395-66741-06
Application Number	Currently unknown 10/535523
Filing Date	May 17, 2005
First Named Inventor	Hodge
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
/AB/		5,928,881	7/27/1999	Barnette et al.
/AB/		6,080,576	6/27/2000	Zambrowicz et al.
/AB/		6,136,566	10/24/2000	Sands et al.
/AB/		6,139,833	10/31/2000	Burgess et al.
/AB/		6,207,371	3/27/2001	Zambrowicz et al.
/AB/		6,218,123	4/17/2001	Nehls et al.
/AB/		6,436,707	8/20/2002	Zambrowicz et al.
/AB/		6,448,000	9/10/2002	Rubin et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
/AB/		WIPO	WO 97/45543 A2	04.12.1997	The Government of the USA, as represented by the Secretary of the Dept. of Health and Human Services, National Institutes of Health
/AB/		WIPO	WO 01/83754 A2	08.11.2001	Immusol, Incorporated
/AB/		WIPO	WO 02/44321 A2	06.06.2002	Max-Planck-Gesellschaft Zur Förderung der Wissenschaften E.V.

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6395-66741-06
Application Number	10/535523
Filing Date	May 17, 2005
First Named Inventor	Hodge
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
/AB/		Froeyen et al., "RNA as a Target for Drug Design, the Example of Tat-TAR Interaction," <i>Curr. Top. Med. Chem.</i> 2:1123-1145 (2002).
/AB/		Gitlin et al., "Short Interfering RNA Confers Intracellular Antiviral Immunity in Human Cells," <i>Nature</i> 418:430-434 (2002).
/AB/		Gulakowski et al., "A Semiautomated Multiparameter Approach for Anti-HIV Drug Screening," <i>J. Virol. Methods</i> 33:87-100 (1991).
/AB/		Hata et al., "A Simple Purification And Fluorescent Assay Method Of The Poliovirus 3C Protease Searching For Specific Inhibitors," <i>J. Virol. Methods.</i> 84:117-126 (2000).
/AB/		Kashani-Sabet, "Ribozyme Therapeutics," <i>JID Symposium Proceedings</i> 7:76-78 (2002).
/AB/		Manetta et al., "Design and Implementation of a Particle Concentration Fluorescence Method for the Detection of HIV-1 Protease Inhibitors," <i>Anal. Biochem.</i> 202(1):10-15 (1992).
/AB/		Marschall et al., "Inhibition of Gene Expression with Ribozymes," <i>Cell Mol. Neurobiol.</i> 14:523-538 (1994).
/AB/		Scherr et al., "Gene Silencing Mediated by Small Interfering RNAs in Mammalian Cells," <i>Curr. Med. Chem.</i> 10:245-256 (2003).
/AB/		Singh et al., "The Complestatins as HIV-1 Integrase Inhibitors. Efficient Isolation, Structure Elucidation, and Inhibitory Activities of Isocomplestatin, Chloropeptin I, New Complestatins A and B, and Acid-Hydrolysis Products of Chloropeptin I," <i>J. Natl. Prod.</i> 64:874-882 (2001).
/AB/		Ueda et al., "An In Vitro System for Screening Anti-Hepatitis B. Virus Drugs," <i>Virology</i> 169:213-216 (1989).

EXAMINER SIGNATURE: /Agnieszka Boesen/	DATE CONSIDERED: 10/14/2008
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	